Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Celecoxib ‘should not be used’ as adjuvant therapy for stage III colon cancer

Publish date:: June 4, 2020

Key clinical point: Adding celecoxib to standard adjuvant chemotherapy with the FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) regimen did not improve survival for patients with stage III colon cancer.

Major finding: The 3-year disease-free survival rate was 76.3% in the celecoxib arm and 73.4% in the placebo arm. The 5-year overall survival was 84% and 81.8%, respectively.

Study details: A randomized trial of 2,526 patients with resected stage III colon cancer.

Disclosures: The trial was sponsored by the Alliance for Clinical Trials in Oncology in collaboration with the National Cancer Institute. Pfizer provided the celecoxib and placebo. Dr. Meyerhardt disclosed relationships with Cota Healthcare, Taiho Pharmaceutical, and Array BioPharma.

Citation:

Meyerhardt JA et al. ASCO 2020, Abstract 4003.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,